+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Neuroblastoma Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768134
  • Report
  • April 2019
  • Region: Global
  • 238 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • APEIRON Biologics AG
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc
  • United Therapeutics Corp
  • MORE
The global clinical trial report- “2019 Neuroblastoma Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Neuroblastoma. It presents in-depth analysis of Neuroblastoma clinical trials across markets and companies. The research work is for providing complete understanding into trends in Neuroblastoma.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Neuroblastoma clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Neuroblastoma

The research work is prepared through extensive and continuous research on Neuroblastoma trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Neuroblastoma patients are identified
  • The report includes panorama of Neuroblastoma clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Neuroblastoma clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • APEIRON Biologics AG
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc
  • United Therapeutics Corp
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Neuroblastoma Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Neuroblastoma Clinical Trials by Region
2.2.2 Average Enrollment of Neuroblastoma Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Neuroblastoma Treatment, 2019

3. Region wise Neuroblastoma Clinical Trials
3.1 Asia Pacific Neuroblastoma Clinical Trials by Country
3.2 Europe Neuroblastoma Clinical Trials by Country
3.3 North America Neuroblastoma Clinical Trials by Country
3.4 Middle East and Africa Neuroblastoma Clinical Trials by Country
3.5 South and Central America Neuroblastoma Clinical Trials by Country

4. Neuroblastoma Clinical Trial Trends
4.1 Start Year wise Neuroblastoma Clinical Trials
4.2 Phase wise Neuroblastoma Clinical Trials
4.3 Trial Status wise Neuroblastoma Clinical Trials
4.4 Trial Type wise Neuroblastoma Clinical Trials

5. Neuroblastoma Average Enrollment Trends
5.1 Average Enrollment in Neuroblastoma Trials by Year
5.2 Average Enrollment in Neuroblastoma Trials by Phase
5.3 Average Enrollment in Neuroblastoma Trials by Status
5.4 Average Enrollment in Neuroblastoma Trials by Type of Trial

6. Companies Participating in Neuroblastoma Clinical Trials
6.1 Neuroblastoma Trials by Sponsor Type
6.2 Neuroblastoma Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Neuroblastoma Trials- Phase 1
7.2 Neuroblastoma Trials- Phase 2
7.3 Neuroblastoma Trials- Phase 3
7.4 Neuroblastoma Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Neuroblastoma Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Neuroblastoma Clinical Trials and Enrolment
Figure 5: Europe - Country wise Neuroblastoma Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Neuroblastoma Clinical Trials and Enrolment
Figure 7: North America - Country wise Neuroblastoma Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Neuroblastoma Clinical Trials and Enrolment
Figure 9: Neuroblastoma Clinical Trials by Phase
Figure 10: Neuroblastoma Clinical Trials by Trial Status
Figure 11: Neuroblastoma Clinical Trials by Type
Figure 12: Neuroblastoma Clinical Trials by Sponsor Type
Figure 13: Neuroblastoma Clinical Trials by Leading Sponsors
Figure 14: Neuroblastoma Average Enrollment by Phase
Figure 15: Neuroblastoma Average Enrollment by Trial Status
Figure 16: Neuroblastoma Average Enrollment by Type
Figure 17: Neuroblastoma- Average Enrolment by Type of Sponsors
Figure 18: Neuroblastoma- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Neuroblastoma Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Neuroblastoma Clinical Trials and Enrolment
Table 5: Europe - Country wise Neuroblastoma Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Neuroblastoma Clinical Trials and Enrolment
Table 7: North America - Country wise Neuroblastoma Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Neuroblastoma Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Neuroblastoma Average Enrollment by Phase
Table 15: Neuroblastoma Average Enrollment by Trial Status
Table 16: Neuroblastoma Average Enrollment by Type
Table 17: Neuroblastoma- Average Enrolment by Type of Sponsors
Table 18: Neuroblastoma- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Children’s Cancer and Leukaemia Group
  • Children's Healthcare of Atlanta Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • United Therapeutics Corp
  • Y-mAbs Ther
Note: Product cover images may vary from those shown
Adroll
adroll